The biotech deal making space in May 2022 saw Chinese drugmakers licensing out their assets for as much as a billion dollars. MSD and Turning Point Therapeutics gained China-originated cancer drugs in deals worth $2.63 billion.
Huadong Medicine announced a series of three in-licensing deals with a combined value of $1.667 billion, pushing the total deal value for February to $1.883 billion, edging over the $1.681 billion the previous month.
In November and December 16 and 21 licensing deals were reached, respectively. December boasted the second highest number of deals for the year, including 18 in-licensing deals from overseas, seven out-licensed deals and 12 deals between Chinese pharmaceutical firms.
Chinese drugmakers struck 14 licensing deals in October with five of them exceeding $100 million. Hansoh Pharma announced two big deals worth nearly $2 billion in total to mark its foray into siRNA therapeutics.
Among the 22 deals Chinese drugmakers closed in September, 14 were worth $2.566 billion. Everest Medicines and Innovent Biologics dominated the dealmaking space with deals worth $1.06 billion and $529 million, respectively, representing 62% of the total value of all disclosed deals.